Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 10/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7663936 | 0.98 | CAMK2D (0.39) | CAMK2DPIM1KDRGSK3BCNR2 | |
| SCHEMBL7664149 | 0.97 | CAMK2D (0.41) | CAMK2DPIM1KDRGSK3B | |
| SCHEMBL7665495 | 0.96 | CAMK2D (0.41) | CAMK2DPIM1KDRGSK3B | |
| SCHEMBL7664768 | 0.89 | CAMK2D (0.46) | CAMK2DPIM1KDRGSK3BCNR2 | |
| SCHEMBL7666393 | 0.88 | CAMK2D (0.36) | CAMK2DGSK3BCNR2 | |
| SCHEMBL7662560 | 0.87 | PDE4B (0.40) | GSK3B | |
| SCHEMBL7663917 | 0.87 | PDE4A (0.38) | CNR2 | |
| SCHEMBL7655234 | 0.87 | CAMK2D (0.40) | CAMK2DPIM1KDRGSK3BCNR2 | |
| SCHEMBL7662107 | 0.87 | CAMK2D (0.45) | CAMK2DPIM1KDRGSK3BCNR2 | |
| SCHEMBL7653829 | 0.86 | CNR2 (0.36) | CAMK2DGSK3BCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1071683-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999046264-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 1999-09-16 | — | — | WO | disclosed |